Clinical trials: Malignant Neoplasm of Prostate
Prostate Cancer
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Prostate cancer is a common and important health issue. Although effective treatment is often available for localized disease, metastatic prostate cancer remains incurable.
- Trial name
- NCT00574769
- Testing
- RAD001, Docetaxel, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Prostate Cancer, Prostate Neoplasm
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
The purpose of this research study is to learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy.
- Trial name
- NCT03424850
- Testing
- HDR brachytherapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies the safety, tolerability and how well durvalumab and tremelimumab work in treating participants with castration-resistant prostate cancer who have not received chemotherapy (chemotherapy naïve) and has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03204812
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatectomy, Prostate Neoplasm
The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
The goal of this observational study was to compare the perioperative outcomes, postoperative urinary control rates and positive surgical margin (PSM) rates of the robot-assisted laparoscopic radical prostatectomy combined…
- Trial name
- NCT06020287
- Testing
- the robot-assisted laparoscopic radical prostatectomy
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Nanjing University School of Medicine
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostatic Neoplasms, Castration-Resistant
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
The primary objective was to confirm the effect of tasquinimod in delaying disease progression or death as compared with placebo in chemo-naïve patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- TasQ003 (NCT02057666)
- Testing
- Tasquinimod
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 146 people
- Sponsor
- Ipsen
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma
- Trial name
- NCT02499835
- Testing
- Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Cancer, Prostate Cancer
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084825
- Testing
- Docetaxel, Imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate…
- Trial name
- NCT00401765
- Testing
- CNTO 328, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Centocor, Inc.
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
BKM120 in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K).
- Trial name
- NCT01385293
- Testing
- BKM120
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew J. Armstrong, MD
Prostatic Neoplasms, Castration-Resistant
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic…
- Trial name
- NCT05169684
- Testing
- BMS-986218, Docetaxel, Nivolumab
- Where
- 31 sites in United States, France and 1 more
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology
This is a minimal risk correlative clinical blood-drawing protocol. The objective of this lead in pilot component is to determine whether Circulating Tumor Cells (CTC's) can be captured using the novel mesenchymal-marker based…
- Trial name
- NCT02022904
- Testing
- Near infrared (NIR) emissive nanotechnology
- Sponsor
- Duke University
Recurrent Prostate Cancer
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
The purpose of this study is to collect prostate cancer tissue from males with metastatic prostate cancers in order to study the tumor microenvironment (TME), which is the area surrounding the tumor including cells, blood…
- Trial name
- NCT05304858
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Prostate Cancer, Radiotherapy Side Effect
Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
- Conditions
- Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer
- Trial name
- Hypo-M1 (NCT04612907)
- Testing
- Moderate hypo-fractionation, Ultra-hypo-fractionation
- Where
- Sweden
- Volunteers
- 420 people
- Sponsor
- Umeå University
Prostate Cancer, Prostate Neoplasm
MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection
With the general acceptance of MRI and technical advances in biopsy technique of the prostate, new questions arise concerning the selection of patients, the approach, the appropriate technique, the lesions to target and the…
- Trial name
- PROSOVI (NCT03819751)
- Testing
- MRI-targeted prostate biopsy
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of…
- Trial name
- COBRA (NCT05249127)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Spina Bifida, Urothelial Neoplasm
Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate
Different clinical conditions can require urinary bladder augmentation or replacement. Tissue engineered bladder has been clinically evaluated but is not recommended due to diverse side effects.
- Conditions
- Spina Bifida, Urothelial Neoplasm, Bladder, Neurogenic, Bladder Exstrophy
- Trial name
- IMOPU (NCT03698721)
- Testing
- Transurethral Resection of Prostate
- Volunteers
- 365 people
- Sponsor
- Central Hospital, Nancy, France
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland